Pharmaceuticals, Biotech & Life Sciences Brands · Advertiser / Brand
Lilly
Public pharmaceutical company developing, manufacturing and marketing human medicines.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Eli Lilly and Company
- Entity type
- COMPANY
- Founded
- 1876
- Headquarters
- Indianapolis, United States
- Company size
- >5,000
- Market cluster / sector
- Pharmaceuticals, Biotech & Life Sciences Brands
- Market role
- Advertiser / Brand
- Ticker
- LLY
- Official website
- lilly.com
What Lilly does
Lilly funds scientific discovery and clinical development, secures regulatory approvals, manufactures medicines, and commercialises approved products through healthcare distribution and reimbursement channels. It creates value by supplying regulated prescription medicines to healthcare systems and patients, with revenue generated from product sales rather than software subscriptions or advertising services.
Category differentiation
Lilly is a pharmaceutical manufacturer and medicine marketer, not a healthcare software vendor, pharmacy chain or medical-device manufacturer. It is distinct from companies using the Lilly name in unrelated consumer or services markets.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Eli Lilly and Company is a publicly listed United States pharmaceutical company headquartered in Indianapolis, Indiana. It discovers, develops, manufactures and markets human pharmaceutical products through a single operating segment. The company trades as Lilly, is listed on the New York Stock Exchange under LLY, and reported $65.179 billion in revenue and 51,388 employees worldwide in the supplied company materials. Lilly generates revenue from the sale of prescription medicines. Its commercial customers and access stakeholders include healthcare providers, hospitals and health systems, wholesalers and distributors, insurers and public payers; its medicines are ultimately used by patients. The company operates internationally, including through a German subsidiary.
Company news briefing
Briefing updated:
Eli Lilly has achieved record financial performance, highlighted by a 39% revenue growth driven by strong demand for its GLP-1 portfolio. To navigate shifting employer coverage and target Medicare Part D enrollees, the company launched the GLP-1 Bridge Program supported by targeted consumer awareness campaigns. These commercial successes and strong earnings have reinforced investor confidence, positioning Lilly as a prominent defensive asset amid wider market rotations.
Business model & monetisation
Lilly monetises through sales of human pharmaceutical products. Commercial realisation is driven by medicine purchasing, distribution, prescribing and reimbursement across private and public healthcare systems; no Products Info input identifies subscription, licensing, media-arbitrage or transaction-take-rate pricing.
- Human pharmaceutical product sales
- One-time Sale
Products & capabilities
No products with linked sources are available in this view.
Unlock Full Intelligence Profile for Lilly
Get unlimited access to corporate ownership, historical M&A transactions, verified tech stack telemetry, and live market signals in the interactive Knowledge Graph.
Verified Ownership & Corporate Hierarchy
Complete corporate hierarchy traversal, shareholder cap table history, and parent holding links sourced from regulatory filings.
360° Tech Stack & Vendor Telemetry
Technical header bidding configurations, sellers.json registry nodes, CMP disclosures, and direct programmatic supply chains.
Live Market Signals & Executive Briefings
Continuous 24/7 monitoring of material M&A deals, executive shifts, product rollouts, and hiring trends across peer entities.
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Lilly's competitive landscape.
Biopharmaceutical company developing and commercialising prescription medicines.
Global pharmaceutical company selling medicines and vaccines.
US pharmacy retailer delivering prescriptions, healthcare services, consumer goods and retail media.
Large public healthcare manufacturer and commercial products company.
Diversified life sciences company spanning pharmaceuticals, consumer health and agriculture.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
West Pharma earnings prove it's not just a GLP-1 play
Financials · Recorded impact score: 2/5
West Pharmaceutical Services reported strong Q3 2026 earnings, with adjusted EPS up 35.7% to $2.66 on sales of $874.5 million, beating analyst expectations. The company raised its full-year adjusted EPS guidance to $9.38-$9.48, citing robust demand for its premium drug-delivery components. While the GLP-1 boom, highlighted by Eli Lilly's 39% revenue growth, is a tailwind, West's growth is also driven by high-value component sales and margin expansion. Proprietary product sales grew 12.6%, with high-value components up 20.3% and now representing 53% of sales. Management expects operating margins to expand by nearly 300 basis points this year, supported by disciplined capital spending. The stock hit a 52-week high of $438.27, reflecting investor confidence in the company's diversified growth strategy.
- West Pharmaceutical Services reported Q3 2026 adjusted EPS of $2.66, up 35.7% year-over-year.
- Q3 sales rose 8.7% to $874.5 million.
10-Q Financial Filing Analysis for Lilly (2026-10-29)
financials · Recorded impact score: 4.6/5
Eli Lilly and Company reported strong financial results for the third quarter of 2026, driven by rapid uptake of its incretin portfolio. Total revenue reached $24.40 billion, up 39% year-over-year from $17.60 billion in Q3 2025, underpinned by massive volume expansion for Mounjaro ($10.72 billion, up 65%) and Zepbound ($5.35 billion, up 49%). Incretin medicines represented roughly two-thirds of total revenue for the first nine months of 2026. Consolidated net income for the quarter rose 16% to $6.45 billion ($7.22 diluted EPS), despite absorbing $4.18 billion in acquired in-process research and development (IPR&D) charges from external business development transactions including AtaiBeckley and Curevo. Operating cash flow expanded to $27.42 billion for the first nine months, allowing Lilly to fund aggressive manufacturing expansions ($8.44 billion in CapEx), strategic acquisitions ($10.69 billion net cash paid for acquisitions), and shareholder returns ($4.64 billion in dividends and $4.33 billion in share repurchases). While lower realized prices in the U.S. and China created pricing headwinds, Lilly's manufacturing efficiencies supported an 83.9% gross margin. Management continues to monitor pricing pressures from the Inflation Reduction Act, international reference pricing, and ongoing litigation regarding incretin compounding and patent enforcement.
- Q3 2026 revenue increased 39% year-over-year to $24.40 billion, with Mounjaro generating $10.72 billion and Zepbound generating $5.35 billion.
- Quarterly net income reached $6.45 billion ($7.22 diluted EPS), absorbing $4.18 billion in acquired in-process R&D charges primarily from asset acquisitions of AtaiBeckley and Curevo.
Eli Lilly Debuts GLP-1 Ad Targeting Medicare Enrollees
Brand Marketing / Advertising Campaign · Recorded impact score: 2/5
Eli Lilly and Wieden+Kennedy Portland premiered a film called “A Life Covered” to raise awareness among Medicare Part D enrollees about newly available coverage for certain GLP-1 weight-management medications under a CMS demonstration called the Medicare GLP-1 Bridge. The ad — credited to directors Kwedar and Bentley, shot by Linus Sandgren and scored by Caroline Shaw — aims to inform seniors about access and cost (noted as $50/month under the demonstration). Lilly positioned the spot as a consumer awareness effort for patients and seniors; the campaign continues a multi-year partnership between Lilly and Wieden+Kennedy.
- Eli Lilly and Wieden+Kennedy Portland debuted a film titled “A Life Covered.”
- As of July 1, eligible Medicare Part D enrollees can receive certain GLP-1 medications for weight management at $50/month under a CMS demonstration called the Medicare GLP-1 Bridge.
Eli Lilly Selects Veeva Vault CRM Globally
Customer Relationship Management (CRM) · Recorded impact score: 2/5
Veeva Systems announced that Eli Lilly and Company has committed to Veeva Vault CRM for global deployment. Vault CRM, part of Veeva's Vault CRM Suite, is described as the technology foundation for “agentic commercial,” a commercial model that leverages AI to deliver medicines to patients. Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly, and Veeva CEO Peter Gassner are quoted on the strategic expansion. Veeva is described as an industry cloud provider for life sciences serving more than 1,500 customers and operating as a Public Benefit Corporation. The announcement was distributed via PR Newswire and published on MarTech Series on August 11, 2026.
- Veeva Systems announced that Eli Lilly and Company has committed to Veeva Vault CRM globally.
- Vault CRM is part of the Vault CRM Suite and is positioned as the technology foundation for the 'agentic commercial' model that leverages AI.
Explore company relationships
Questions about Lilly
What is Eli Lilly and Company?
Eli Lilly and Company is a publicly listed pharmaceutical company that discovers, develops, manufactures and markets human medicines.
Who uses Lilly?
Lilly medicines are used by patients and accessed through healthcare providers, hospitals, distributors, insurers and public healthcare payers.
How does Lilly make money?
Lilly generates revenue primarily from sales of human pharmaceutical products.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
12 publicly documented primary sources and citations linked across the market graph.
Continue your research on Lilly
Open additional company details, personal Watchlists and your Strategic Intelligence Agent in Polaris7. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Daily intelligent monitoring · Verified primary sources.
Unlock full intelligence profile, ownership & live market signals